clinical research prime

Pediatric Influenza

Treatment Study

• Between the ages of 3 weeks – 11 years.
• A Phase 3b open – label surveillance study of susceptibility to BALOXAVIR MARBOXIL in pediatric patients with Influenza and transmission of Influenza to household contacts.
• Participants will receive study related treatment at no cost and will be compensated for time and travel.